Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00097591 · ClinicalTrials.gov registry record · Phase 3
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 13,619
- Enrollment target
NCT00097591: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT00097591 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 13,619 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1666% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00097591, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 13,619 participants
- Enrollment target
Study Summary
The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a percutaneous coronary intervention (PCI; also called a balloon angioplasty). Prasugrel was compared with Clopidogrel to determine which drug is better at reducing deaths, future heart attacks, or stroke.
Primary Outcome
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI).
Interventions
- DRUG Clopidogrel
- DRUG Prasugrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,619 participants |
| Start Date | 2004-11 |
| Est. Completion | 2007-07 |
| Phase | Phase 3 |
What the finished NCT00097591 record still lists
NCT00097591 is an interventional study that assigns participants to a tested intervention. Its 13,619 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1666% higher).
The record links to 0 conditions, and to 2 interventions - of which Clopidogrel is the first listed.
NCT00097591 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00097591 about?
NCT00097591 is a clinical study titled "A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention". The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a percutaneous coronary intervention (PCI; also called a balloon angioplasty). P...
What is the current status of trial NCT00097591?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 13,619 participants. The study started on 2004-11. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00097591?
The interventions under investigation include: Clopidogrel (DRUG), Prasugrel (DRUG).
Who is sponsoring clinical trial NCT00097591?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00097591's enrollment target sits among peer trials
13,619 17th of 2000 higher than 1,984 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06058767 · 13,764 participants · NA
Preschool Hearing Screening
- NCT05141396 · 13,400 participants · NA
Telehealth-Enabled, Real-time Audit and Feedback for Clinician AdHerence (TEACH)
- NCT05991453 · 13,000 participants · NA
Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial
- NCT07177352 · 13,000 participants · Phase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia